ESMO 2019 | FLAURA final analysis: osimertinib for first-line EGFRm NSCLC

Suresh Ramalingam

Suresh Ramalingam, MD, FASCO, of Winship Cancer Institute, Emory University, Atlanta, GA, discusses the final overall survival analysis of the FLAURA trial (NCT02296125) at the European Society for Medical Oncology (ESMO) congress 2019 in Barcelona, Spain. The study compared osimertinib to comparator EGFR-TKI as a first-line treatment for EGFR mutated advanced non-small cell lung cancer, and found the median progression-free survival to be significantly longer with osimertinib. Following this, Pilar Garrido, MD, PhD, from the University of Alcalá, Madrid, Spain, gives her thoughts on the results.

Share this video